Outcomes in COVID-19 PPE studies
Outcomes in PPE studies. Only RCTs are included.
0
0.5
1
1.5+ All studies 2% 4 351,091 Improvement, Studies, Patients Relative Risk Cases 2% 4 351,091 RCTs 2% 4 351,091 Prophylaxis 2% 4 351,091 PPE for COVID-19 c19 earlyMarch 2025 Favors PPE Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ DANMASK-19 Bundgaard (RCT) 18% 0.82 [0.54-1.23] cases 42/2,392 53/2,470 Improvement, RR [CI] Treatment Control Abaluck (RCT) 9% 0.91 [0.81-0.99] symp. case 178,322 (n) 163,861 (n) TRACE/STOPCOV Smith (SB RCT) -98% 1.98 [0.97-4.03] cases 137 (n) 108 (n) Solberg (RCT) -7% 1.07 [0.58-1.96] cases 21/1,834 21/1,967 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Prophylaxis 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk All studies 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk 4 PPE COVID-19 studies c19 earlyMarch 2025 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Effect extraction pre-specified (most serious outcome) Favors PPE Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ DANMASK-19 Bundgaard (RCT) 18% 0.82 [0.54-1.23] cases 42/2,392 53/2,470 Improvement, RR [CI] Treatment Control Abaluck (RCT) 9% 0.91 [0.81-0.99] symp. case 178,322 (n) 163,861 (n) TRACE/STOPCOV Smith (SB RCT) -98% 1.98 [0.97-4.03] cases 137 (n) 108 (n) Solberg (RCT) -7% 1.07 [0.58-1.96] cases 21/1,834 21/1,967 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Prophylaxis 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk All studies 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk 4 PPE COVID-19 case results c19 earlyMarch 2025 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Favors PPE Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ DANMASK-19 Bundgaard (RCT) 18% 0.82 [0.54-1.23] cases 42/2,392 53/2,470 Improvement, RR [CI] Treatment Control Abaluck (RCT) 9% 0.91 [0.81-0.99] symp. case 178,322 (n) 163,861 (n) TRACE/STOPCOV Smith (SB RCT) -98% 1.98 [0.97-4.03] cases 137 (n) 108 (n) Solberg (RCT) -7% 1.07 [0.58-1.96] cases 21/1,834 21/1,967 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Prophylaxis 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk All studies 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk 4 PPE COVID-19 Randomized Controlled Trials c19 earlyMarch 2025 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Effect extraction pre-specified (most serious outcome) Favors PPE Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ DANMASK-19 Bundgaard (RCT) 18% 0.82 [0.54-1.23] cases 42/2,392 53/2,470 Improvement, RR [CI] Treatment Control Abaluck (RCT) 9% 0.91 [0.81-0.99] symp. case 178,322 (n) 163,861 (n) TRACE/STOPCOV Smith (SB RCT) -98% 1.98 [0.97-4.03] cases 137 (n) 108 (n) Solberg (RCT) -7% 1.07 [0.58-1.96] cases 21/1,834 21/1,967 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Prophylaxis 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk All studies 2% 0.98 [0.76-1.25] 63/182,685 74/168,406 2% lower risk 4 PPE COVID-19 peer reviewed studies c19 earlyMarch 2025 Tau2 = 0.03, I2 = 41.5%, p = 0.87 Effect extraction pre-specified (most serious outcome) Favors PPE Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ DANMASK-19 Bundgaard (RCT) 18% 0.82 [0.54-1.23] cases 42/2,392 53/2,470 Improvement, RR [CI] Treatment Control Abaluck (RCT) 9% 0.91 [0.81-0.99] symp. case 178,322 (n) 163,861 (n) TRACE/STOPCOV Smith (SB RCT) -98% 1.98 [0.97-4.03] cases 137 (n) 108 (n) TRACE/STOPCOV Smith (SB RCT) -58% 1.58 [0.29-8.45] cases 4/137 2/108 TRACE/STOPCOV Smith (SB RCT) -164% 2.64 [0.89-7.80] misc. 137 (n) 108 (n) TRACE/STOPCOV Smith (SB RCT) -373% 4.73 [0.58-38.7] misc. 6/137 1/108 TRACE/STOPCOV Smith (SB RCT) -176% 2.76 [0.58-13.0] misc. 7/137 2/108 TRACE/STOPCOV Smith (SB RCT) -358% 4.58 [0.22-94.3] misc. 2/137 0/108 TRACE/STOPCOV Smith (SB RCT) 69% 0.31 [0.01-7.44] misc. 0/137 1/108 Solberg (RCT) -7% 1.07 [0.58-1.96] cases 21/1,834 21/1,967 PPE COVID-19 outcomes c19 earlyMarch 2025 Favors PPE Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
